Attached files
file | filename |
---|---|
EX-23.1 - EX-23.1 - Sagent Pharmaceuticals, Inc. | d855921dex231.htm |
EX-31.1 - EX-31.1 - Sagent Pharmaceuticals, Inc. | d855921dex311.htm |
EX-23.2 - EX-23.2 - Sagent Pharmaceuticals, Inc. | d855921dex232.htm |
EX-31.2 - EX-31.2 - Sagent Pharmaceuticals, Inc. | d855921dex312.htm |
EX-21.1 - EX-21.1 - Sagent Pharmaceuticals, Inc. | d855921dex211.htm |
EX-32.1 - EX-32.1 - Sagent Pharmaceuticals, Inc. | d855921dex321.htm |
EXCEL - IDEA: XBRL DOCUMENT - Sagent Pharmaceuticals, Inc. | Financial_Report.xls |
10-K - 10-K - Sagent Pharmaceuticals, Inc. | d855921d10k.htm |
Exhibit 23.3
Consent of Independent Auditors
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-200027) of Sagent Pharmaceuticals, Inc. |
(2) | Registration Statements (Form S-8 No. 333-175352) pertaining to the 2007 Global Share Plan of Sagent Holding Co. and the 2011 Incentive Compensation Plan of Sagent Pharmaceuticals, Inc. |
of our report dated March 16, 2015, with respect to the financial statements of Sagent Agila LLC., included in the Annual Report (Form 10-K) of Sagent Pharmaceuticals, Inc. for the year ended December 31, 2014.
/s/ Ernst and Young LLP
Chicago, Illinois
March 16, 2015